Table 1.

Selected reports on gynecomastia prevalence after treatment with finasteride (5 mg/day)

Number affected (%)	Comments	References
214 men reported in FDA adverse drug event surveillance	Side affected: 30% unilateral, 25% bilateral, 45% unspecified. Remission: 80% partial or complete remission, 20% no change. Cancer risk: One patient suspected to develop intraductal breast carcinoma due to treatment.	9
42/14722 (0.3)	Third most common side effect of finasteride. Rate of gynaecomastia was 0.26/1000 patient-months of therapy.	8
1/297 (0.3)		11
426/9423 (4.5)		12
0/70 (0)		2